Active	Status	Sponsor type	Region	Phase	Filter
5 Active 6 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Marder, Stephen R
NCT03245437: Target Engagement and Response to Oxytocin	Active, not recruiting	4	120	US	Oxytocin nasal spray, OT, Social Cognition Skills Training, SCST, Health Management, HM, Placebo nasal spray, PBO	University of California, Los Angeles, National Institute of Mental Health (NIMH)	Schizophrenia	07/24	07/24
NCT03437668: Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia	Terminated	2/3	47	US	WSE, Withania somnifera extracts, Ashwagandha, Sensoril®, Placebo Oral Tablet	Chengappa, K.N. Roy, MD, Stanley Medical Research Institute, University of Maryland	Schizophrenia	06/23	06/23
NCT03900754: A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia	Terminated	2	26	US	Oxytocin, Syntocinon, Placebo	VA Office of Research and Development, University of California, San Francisco, VA Greater Los Angeles Healthcare System	Schizophrenia	01/24	01/24
NCT05790239: MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder	Not yet recruiting	2	40	US	3,4-methylenedioxymethamphetamine, MDMA, d-amphetamine, Therapy	Stephen Robert Marder	Post Traumatic Stress Disorder	05/25	03/26
NCT05204407: Luteolin for the Treatment of People With Schizophrenia	Recruiting	N/A	60	US	Luteolin, PureLut, Placebo	University of Maryland, Baltimore, University of California, Los Angeles, Stanley Medical Research Institute	Schizophrenia, Schizoaffective Disorder	03/25	03/25
DeGroot, Michael H
No trials found